Cargando…

Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles

PURPOSE: Schisandrin B (Sch B) is clinically applied for the treatment of hepatitis and ischemic disease. However, its clinical efficacy is limited due to the poor solubility and low bioavailability. This study aimed to develop matrix metalloproteinase (MMP)-sensitive peptide-modified, polyethylene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Mingfeng, Yang, Wenfang, Han, Guangying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627750/ https://www.ncbi.nlm.nih.gov/pubmed/29026305 http://dx.doi.org/10.2147/IJN.S141549

Ejemplares similares

Beneficial Effects of Schisandrin B on the Cardiac Function in Mice Model of Myocardial Infarction
por: Chen, Pengsheng, et al.
Publicado: (2013)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Matrix metalloproteinases in coronary artery disease and myocardial infarction
por: Bräuninger, Hanna, et al.
Publicado: (2023)

Erratum: Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Schisandrin B regulates lipid metabolism in subcutaneous adipocytes
por: Kwan, Hiu Yee, et al.
Publicado: (2017)

Matrix metalloproteinases and their gene polymorphism in young ST-segment elevation myocardial infarction
por: Basia, Deepak, et al.
Publicado: (2022)

Genetic Polymorphism of Matrix Metalloproteinase-9 and Susceptibility to Myocardial Infarction: A Meta-Analysis
por: Feng, Beili, et al.
Publicado: (2022)

Myocardial Injury Promotes Matrix Metalloproteinase-9 Activity in the Renal Cortex in Preclinical Models of Acute Myocardial Infarction
por: Qiao, Xiaoying, et al.
Publicado: (2021)

Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women
por: Jefferis, Barbara J., et al.
Publicado: (2010)

Prognostic value of tissue inhibitor of metalloproteinase-matrix metalloproteinase biomarkers at 30 days in patients with acute myocardial infarction without reperfusion therapy
por: Pang, Hui-Fang, et al.
Publicado: (2021)

Matrix Metalloproteinase Gene Delivery for Liver Fibrosis
por: Iimuro, Yuji, et al.
Publicado: (2007)

Expression of matrix metalloproteinases-12 in ST-segment elevation myocardial infarction: A case–control study
por: Wang, Jing, et al.
Publicado: (2017)

Schisandrin B for the treatment of male infertility
por: Zou, Di‐Xin, et al.
Publicado: (2021)

Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison With Intramyocardial Cell Delivery
por: Zlabinger, Katrin, et al.
Publicado: (2018)

PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
por: Castillo, Paula M, et al.
Publicado: (2014)

Association of Matrix Metalloproteinase 9 C-1562T Polymorphism with Genetic Susceptibility to Myocardial Infarction: A Meta-Analysis
por: Juan, Zhang, et al.
Publicado: (2015)

PEGylated carboxyhemoglobin bovine (SANGUINATE) ameliorates myocardial infarction in a rat model
por: Kawaguchi, Akira T., et al.
Publicado: (2018)

A PEGylated Nanostructured Lipid Carrier for Enhanced Oral Delivery of Antibiotics
por: Alavi, Seyed Ebrahim, et al.
Publicado: (2022)

Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation
por: Yu, Jianjun, et al.
Publicado: (2018)

Circulating Matrix Metalloproteinase-28 Levels Are Related to GRACE Scores and Short-Term Outcomes in Patients with Acute Myocardial Infarction
por: Zhou, Ke, et al.
Publicado: (2020)

Peptide-Based Selective Inhibitors of Matrix Metalloproteinase-Mediated Activities
por: Ndinguri, Margaret W., et al.
Publicado: (2012)

Differential Action between Schisandrin A and Schisandrin B in Eliciting an Anti-Inflammatory Action: The Depletion of Reduced Glutathione and the Induction of an Antioxidant Response
por: Leong, Pou Kuan, et al.
Publicado: (2016)

The Influence of Autologous Bone Marrow Stem Cell Transplantation on Matrix Metalloproteinases in Patients Treated for Acute ST-Elevation Myocardial Infarction
por: Furenes, Eline Bredal, et al.
Publicado: (2014)

Predictive Utility of the Changes in Matrix Metalloproteinase‐2 in the Early Phase for Left Ventricular Reverse Remodeling After an Acute Myocardial Infarction
por: Morishita, Tetsuji, et al.
Publicado: (2015)

Matrix Metalloproteinase Mediated Type I Collagen Degradation is an Independent Predictor of Increased Risk of Acute Myocardial Infarction in Postmenopausal Women
por: Bertelsen, Ditte Marie, et al.
Publicado: (2018)

Higher levels of TWEAK and matrix metalloproteinase-3 during the acute phase of myocardial infarction are associated with adverse left ventricular remodeling
por: Eyyupkoca, Ferhat, et al.
Publicado: (2021)

Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases–INVITATION Trial–
por: Shirakawa, Takuhiro, et al.
Publicado: (2022)

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma
por: Wei, Minyan, et al.
Publicado: (2015)

Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes
por: Yuan, Zhi-xiang, et al.
Publicado: (2017)

Extracellular Matrix Biomaterial Therapy for Myocardial Infarction: New Delivery Route and Immunomodulatory Effects
por: Christman, Karen L.
Publicado: (2023)

Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles
por: Zhang, Ling, et al.
Publicado: (2013)

Functional relationship between matrix metalloproteinase-11 and matrix metalloproteinase-14
por: Buache, Emilie, et al.
Publicado: (2014)

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
por: HOU, CHUN, et al.
Publicado: (2016)

Matrix Metalloproteinase-9 Relationship With Infarct Growth and Hemorrhagic Transformation in the Era of Thrombectomy
por: Mechtouff, Laura, et al.
Publicado: (2020)

Modified platelet deposition on matrix metalloproteinase 13 digested collagen I
por: Howes, J.‐M., et al.
Publicado: (2015)

Schisandrin B Diet Inhibits Oxidative Stress to Reduce Ferroptosis and Lipid Peroxidation to Prevent Pirarubicin-Induced Hepatotoxicity
por: Shi, Hongwei, et al.
Publicado: (2022)

Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA
por: Ge, Xuemei, et al.
Publicado: (2021)

CHARMM-GUI Membrane Builder for Lipid Nanoparticles with Ionizable Cationic Lipids and PEGylated Lipids
por: Park, Soohyung, et al.
Publicado: (2021)

Matrix metalloproteinases and epileptogenesis
por: Ikonomidou, Chrysanthy
Publicado: (2014)

Matrix Metalloproteinases and Glaucoma
por: Kim, Moo Hyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9olsu4siam8c7nqbm0qcc2cu3q